Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertensio
Not Applicable
- Conditions
- pulmonary hypertension
- Registration Number
- JPRN-UMIN000015696
- Lead Sponsor
- Hokkaido University Hospital, Internal medicine I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1. Those to whom imatinib and sorafenib are contraindicated 2. Those to whom the principle investigator deemed to be unsuitable for enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety (adverse events due to the use of tyrosine kinase inhibitor)
- Secondary Outcome Measures
Name Time Method Efficacy to pulmonary hypertension